Mumbai: Lupin Limited has announced that it has received tentative approval from the United States Food and Drug ...

Supernus Pharmaceuticals is up 1.8% during the same time and is heading into earnings with an average analyst price target of $38.80 (compared to the current share price of $32.84).

Supernus Pharmaceuticals, Inc. Qelbree ® net product sales growth of 179% and 193% in the first three months and first six months of 2023, respectively, compared to the same periods in 2022 $31.0 ...

Supernus Pharmaceuticals SUPN shares soared 5.7% in the last trading session to close at $32.90. The move was backed by solid volume with far more shares changing hands than in a normal session.

Supernus' reliance on Qelbree is increasing, with significant revenue growth in 2024, but generic competition for other drugs poses challenges. Management's 2025 guidance led to a stock sell-off ...

Supernus Pharmaceuticals' stock has risen 15% since my last "strong buy" rating, despite recent analyst downgrades due to Qelbree's slowing growth. Supernus' diverse neuroscience portfolio ...

Zydus allegedly infringed patents with proposed Trokendi generic Parties settled earlier patent dispute in 2017 Complaint says Zydus not allowed to make generic until 2023 (Reuters) - Supernus ...

Supernus Pharmaceuticals Inc., a Rockville-based pharmaceutical company focused on products for the treatment of central nervous system diseases, reported ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...